Mechanisms of Refractory Hypertension (Reserpine)

Refractory Hypertension Clinical Trial

Official title: Mechanisms of Refractory Hypertension (Reserpine)

Status Completed

Clinical Trial Summary

The study is deigned to determine if refractory hypertension is attributable to heightened sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic agent, in patients failing other classes of antihypertensive agents.

Clinical Trial Description

Patients with refractory hypertension, defined as uncontrolled office blood pressure despite use of 5 or more antihypertensive agents, including a thiazide diuretic and spironolactone. After withdrawal from other centrally-acting agents if needed, enrolled patients will be randomized to open-label reserpine 0.1 mg daily for 4 weeks. Twenty-four hour ambulatory blood pressure monitoring will be done at baseline, after the initial 4-week treatment period. All other antihypertensive medications will remain unchanged during the 4-week treatment period. The primary endpoint will be change in 24-hr ambulatory systolic blood pressure. ;

Related Conditions & MeSH terms

• Hypertension
• Refractory Hypertension

• NCT number: NCT03223272
• Study type: Interventional
• Source: University of Alabama at Birmingham
• Status: Completed
• Phase: Phase 2
• Start date: July 23, 2015
• Completion date: January 31, 2020